BioNTech SE

NASDAQ: BNTX
$156.53
-$5.13 (-3.2%)
Closing price January 20, 2022
Thursday afternoon's top analyst upgrades and downgrades included AT&T, BioNTech, Chewy, DocuSign, Ford, GM, Shopify, Toast, and more.
Wednesday afternoon's analyst upgrades and downgrades included BioNTech, ConocoPhillips, Casper Sleep, DoorDash, Palantir and Poshmark.
Here are three companies scheduled to report quarterly results before markets open on Tuesday.
Thursday afternoon's analyst upgrades and downgrades included Amazon, Bank of America, BioNTech, Chipotle, Disney and more.
COVID-19 vaccine co-developer BioNTech reports June quarter earnings before markets open Monday morning. So do two hot stocks in Cathie Wood's ETF portfolio.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Acceleron Pharma, BioNTech, CyberArk Software, Five9 and Vertex Pharmaceuticals.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
After a quiet Friday afternoon, March quarter earnings hit the ground running again before markets open Monday. More than 1,500 earnings reports are expected next week.
Here are five stocks that reported earnings in the past week and all posted better-than-expected numbers and investors rewarded them with higher share prices.
Two interesting earnings reports are due early next week. One is recent entry in the electric vehicle market and the other is a co-developer of a COVID-19 vaccine.
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Tuesday's top analyst upgrades and downgrades included BioNTech, Charles Schwab, FedEx, First Solar, Micron Technologies, Nio, Occidental Petroleum, Salesforce.com, Square and Zoom Video...
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.